Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release.
The effects of ibogaine, a putative anti-addictive drug, on stimulated catecholamine release were examined in cultured chromaffin cells to clarify its mechanism(s) of action. Low concentrations of ibogaine (1-10 microM) had a selective inhibitory action on nicotinic receptor-mediated catecholamine release, while higher concentrations (100 microM) inhibited additional modes of stimulated catecholamine release. These results suggest a selective inhibitory action of ibogaine at the nicotinic acetylcholine receptor, possibly at the receptor ion channel site.
Schneider
A S
AS
Department of Pharmacology and Neuroscience, Albany Medical College, NY 12208, USA.
Nagel
J E
JE
Mah
S J
SJ
D000818:Animals; D002395:Catecholamines / Q000378:metabolism*; D002417:Cattle; D019439:Chromaffin Cells / Q000187:drug effects / Q000378:metabolism; D007050:Ibogaine / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D011188:Potassium / Q000494:pharmacology; D011619:Psychotropic Drugs / Q000494:pharmacology*; D011978:Receptors, Nicotinic / Q000187:drug effects*; D014701:Veratridine / Q000378:metabolism
D002395:Catecholamines; D018733:Nicotinic Antagonists; D011619:Psychotropic Drugs; D011978:Receptors, Nicotinic; D007050:Ibogaine; D014701:Veratridine; D011188:Potassium